$VTYX
Ventyx Biosciences, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024094007 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.923M $7.907M
YoY Change -3.38% -7.9%
% of Gross Profit
Research & Development $30.63M $27.81M
YoY Change -38.43% -42.74%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K
YoY Change 233.33% 194.12%
% of Gross Profit
Operating Expenses $38.55M $35.71M
YoY Change -33.47% -37.51%
Operating Profit -$38.55M -$35.71M
YoY Change -33.47% -37.51%
Interest Expense $3.350M $3.783M
YoY Change -14.76% -2.98%
% of Operating Profit
Other Income/Expense, Net $3.303M $3.762M
YoY Change -15.83% -3.39%
Pretax Income -$35.25M -$31.95M
YoY Change -34.76% -40.0%
Income Tax
% Of Pretax Income
Net Earnings -$35.25M -$31.95M
YoY Change -34.76% -40.0%
Net Earnings / Revenue
Basic Earnings Per Share -$0.50 -$0.45
Diluted Earnings Per Share -$0.50 -$0.45
COMMON SHARES
Basic Shares Outstanding 70.67M 70.50M
Diluted Shares Outstanding 70.67M 70.55M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $274.8M $239.4M
YoY Change -8.64% -27.93%
Cash & Equivalents $61.77M $40.93M
Short-Term Investments $213.1M $198.5M
Other Short-Term Assets $14.58M $17.49M
YoY Change 99.77% 21.07%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $289.4M $256.9M
YoY Change -6.06% -25.89%
LONG-TERM ASSETS
Property, Plant & Equipment $703.0K $762.0K
YoY Change 2.48% 21.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $40.26M
YoY Change
Other Assets $96.00K $102.0K
YoY Change -5.88% 0.0%
Total Long-Term Assets $11.69M $52.26M
YoY Change -14.09% 2434.53%
TOTAL ASSETS
Total Short-Term Assets $289.4M $256.9M
Total Long-Term Assets $11.69M $52.26M
Total Assets $301.1M $309.2M
YoY Change -6.4% -11.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.286M $6.583M
YoY Change -75.52% 61.15%
Accrued Expenses $9.006M $10.55M
YoY Change -45.06% -31.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.30M $18.10M
YoY Change -53.06% -9.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.03M $10.29M
YoY Change -15.76% 1016.49%
Total Long-Term Liabilities $10.03M $10.29M
YoY Change -15.76% 1016.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.30M $18.10M
Total Long-Term Liabilities $10.03M $10.29M
Total Liabilities $22.33M $28.40M
YoY Change -41.34% 35.51%
SHAREHOLDERS EQUITY
Retained Earnings -$525.0M -$489.7M
YoY Change 40.95% 53.8%
Common Stock $7.000K $7.000K
YoY Change 16.67% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $278.8M $280.8M
YoY Change
Total Liabilities & Shareholders Equity $301.1M $309.2M
YoY Change -6.4% -11.35%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$35.25M -$31.95M
YoY Change -34.76% -40.0%
Depreciation, Depletion And Amortization $100.0K $100.0K
YoY Change 233.33% 194.12%
Cash From Operating Activities -$35.46M -$24.54M
YoY Change 2.28% -50.21%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $60.00K
YoY Change -100.0% -69.23%
Acquisitions
YoY Change
Other Investing Activities $29.25M -$75.46M
YoY Change -24.89% -315.51%
Cash From Investing Activities $29.25M -$75.52M
YoY Change -24.81% -316.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 26.86M -906.0K
YoY Change 1558.15% -136.64%
NET CHANGE
Cash From Operating Activities -35.46M -24.54M
Cash From Investing Activities 29.25M -75.52M
Cash From Financing Activities 26.86M -906.0K
Net Change In Cash 20.65M -101.0M
YoY Change 252.96% 742.07%
FREE CASH FLOW
Cash From Operating Activities -$35.46M -$24.54M
Capital Expenditures $0.00 $60.00K
Free Cash Flow -$35.46M -$24.60M
YoY Change 2.16% -50.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001851194
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssets
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssets
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40928
dei Entity Registrant Name
EntityRegistrantName
Ventyx Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-2996852
dei Entity Address Address Line1
EntityAddressAddressLine1
12790 El Camino Real
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
760
dei Local Phone Number
LocalPhoneNumber
593-4832
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
VTYX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70669131
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40925000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51579000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
198513000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
200641000
CY2024Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
17493000
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
12125000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
256931000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
264345000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
762000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
762000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10162000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11509000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
40261000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
975000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
975000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102000
CY2024Q2 us-gaap Assets
Assets
309193000
CY2023Q4 us-gaap Assets
Assets
277693000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6583000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5756000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10550000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15508000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
971000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1001000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18104000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22265000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10294000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11505000
CY2024Q2 us-gaap Liabilities
Liabilities
28398000
CY2023Q4 us-gaap Liabilities
Liabilities
33770000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70662806
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70662806
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59252349
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59239113
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
770745000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
663154000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-248000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-50000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-489709000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419187000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
280795000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
243923000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
309193000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
277693000
CY2024Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
249000
CY2023Q2 vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
109000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
503000
vtyx Research And Development Expenses Related Party
ResearchAndDevelopmentExpensesRelatedParty
359000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27805000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48560000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61552000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83997000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7907000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8585000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15928000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15700000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
35712000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
57145000
us-gaap Operating Expenses
OperatingExpenses
77480000
us-gaap Operating Expenses
OperatingExpenses
99697000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-35712000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-57145000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77480000
us-gaap Operating Income Loss
OperatingIncomeLoss
-99697000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3783000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3899000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7010000
us-gaap Investment Income Interest
InvestmentIncomeInterest
7521000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-52000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3762000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3894000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6958000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7515000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-31950000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
us-gaap Net Income Loss
NetIncomeLoss
-70522000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-119000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-187000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-181000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
352000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32077000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53400000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70720000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91769000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70554718
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70554718
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58556529
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58556529
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66192348
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66192348
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58100261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58100261
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
306996000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
35000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
26000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
114000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5771000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-119000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-8000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-31950000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
280795000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
371618000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1507000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7868000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-187000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
327807000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
243923000
vtyx Issuance Of Common Stock From Private Placement Net Of Issuance Costs
IssuanceOfCommonStockFromPrivatePlacementNetOfIssuanceCosts
95046000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
118000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
114000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12314000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-181000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-17000
us-gaap Net Income Loss
NetIncomeLoss
-70522000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
280795000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
353895000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48408000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2624000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
214000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14435000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
352000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
327807000
us-gaap Profit Loss
ProfitLoss
-70522000
us-gaap Profit Loss
ProfitLoss
-92182000
us-gaap Depreciation
Depreciation
135000
us-gaap Depreciation
Depreciation
65000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-100000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
88000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
589000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
208000
us-gaap Share Based Compensation
ShareBasedCompensation
12314000
us-gaap Share Based Compensation
ShareBasedCompensation
14435000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-4793000
vtyx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-4569000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5391000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1515000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-377000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-197000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
828000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2371000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4958000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5923000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-72163000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80203000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
176160000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
172821000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
142640000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
189000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
255000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-33755000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15924000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
95046000
vtyx Proceeds From Issuance Of Common Stock From At The Market Offering Net Of Commissions And Offering Expenses
ProceedsFromIssuanceOfCommonStockFromAtTheMarketOfferingNetOfCommissionsAndOfferingExpenses
48408000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
118000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2570000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
114000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
214000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
73000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95278000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51119000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-14000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10654000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13102000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52554000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64819000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41900000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51717000
us-gaap Noncash Or Part Noncash Acquisition Inventory Acquired1
NoncashOrPartNoncashAcquisitionInventoryAcquired1
30000
vtyx Exercise Of Stock Options
ExerciseOfStockOptions
54000
vtyx Deferred Offering Costs Unpaid
DeferredOfferingCostsUnpaid
66000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40925000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51717000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
975000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41900000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51717000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
238924000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
22000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
172000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
238774000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
200612000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
145000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
116000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
200641000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
25
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
25
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
10
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
10
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
8
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
2
CY2024Q2 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
0
CY2024Q2 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
500000
CY2023Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
800000
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1104000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1021000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
342000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
259000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
762000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
762000
CY2024Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
100000
CY2024Q2 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1715000
CY2023Q4 vtyx Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
1868000
CY2024Q2 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
4512000
CY2023Q4 vtyx Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
4831000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3147000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7742000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1010000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
984000
CY2024Q2 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
166000
CY2023Q4 vtyx Accrued Related Party Liabilities Current
AccruedRelatedPartyLiabilitiesCurrent
83000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10550000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15508000
CY2023 us-gaap Severance Costs1
SeveranceCosts1
2200000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of outstanding shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders.
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15536795
CY2021Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-06-30
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The Company exercised its option to extend the lease term through June 30, 2026,
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
CY2024Q1 vtyx Number Of Termination Agreement
NumberOfTerminationAgreement
2
CY2024Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-06-30
us-gaap Lessee Operating Lease Option To Terminate
LesseeOperatingLeaseOptionToTerminate
The leases contain various termination options
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
600000
us-gaap Operating Lease Cost
OperatingLeaseCost
1200000
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0
us-gaap Variable Lease Cost
VariableLeaseCost
200000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
us-gaap Operating Lease Payments
OperatingLeasePayments
1000000
us-gaap Operating Lease Payments
OperatingLeasePayments
300000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1018000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2073000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2135000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2199000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2265000
CY2024Q2 vtyx Lessee Operating Lease Liability Payments Due Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueThereafter
6162000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15852000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4587000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11265000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
971000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10294000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5771000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7868000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12314000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14435000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5771000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7868000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12314000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14435000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10338724
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.42
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M26D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1737000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2044500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.08
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
127996
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1462027
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
17.18
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10793201
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M17D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1142000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10793201
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M17D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1142000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4962290
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
821000
vtyx Number Of Employees Terminated
NumberOfEmployeesTerminated
1
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-31950000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-53251000
us-gaap Net Income Loss
NetIncomeLoss
-70522000
us-gaap Net Income Loss
NetIncomeLoss
-92182000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70554718
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70554718
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58556529
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58556529
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
66192348
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
66192348
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58100261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58100261
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11294798
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9829037
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-094007-index-headers.html Edgar Link pending
0000950170-24-094007-index.html Edgar Link pending
0000950170-24-094007.txt Edgar Link pending
0000950170-24-094007-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vtyx-20240630.htm Edgar Link pending
vtyx-20240630.xsd Edgar Link pending
vtyx-ex10_2.htm Edgar Link pending
vtyx-ex31_1.htm Edgar Link pending
vtyx-ex31_2.htm Edgar Link pending
vtyx-ex32_1.htm Edgar Link pending
vtyx-ex32_2.htm Edgar Link pending
vtyx-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable